An ongoing phase II trial is being conducted to explore the efficacy of the JAK1/2 inhibitor ruxolitinib in patients with R/R lymphoma, including PTCL (NCT01431209). Here, JAK1 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.